All In MedTech

FDA Clearance Tracker · P240003

Minima Stent System and Minima Pro Stent System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Aug 28, 2024 (this decision)Source: openFDAMethods & limitations

PMABreakthrough

Decided

Aug 28, 2024

Approved

Time to decision

180 days

Received Mar 1, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P240003
Device name
Minima Stent System and Minima Pro Stent System
Applicant location
Newport Beach, CA
Received
Mar 1, 2024
Decided
Aug 28, 2024
Decision
Approved
Supplements
8 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code PNF

FDA's approval statement

As written in FDA's record.

The Minima Stent System is indicated for use in the treatment of native or acquired pulmonary artery stenoses or coarctation of the aorta in neonates, infants, and children at least 1.5 kg in weight.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PNF. The earliest in FDA's data is P150028, decided Mar 25, 2016.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Renata Medical, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.